SUNFISH Parts 1 and 2: 5-year efficacy and safety data of risdiplam▼ in Types 2 and 3 spinal muscular atrophy (SMA)
SUNFISH was a multicenter, two-part, randomized, placebo-controlled, double-blind clinical trial of risdiplam▼ in a broad and heterogeneous population with Types 2 and 3 SMA (aged 2–25 years at enrollment). This is the first presentation of motor function and safety data at the end of the 5-year SUNFISH study. Children, teenagers and adults with SMA showed improvement or stabilization in motor function outcomes, which is in contrast to the decline observed in an untreated population.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.